转移性NSCLC-话题@MedSci

#转移性NSCLC#

18篇内容 | 640人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1723673, encodeId=6f671e23673fe, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=2022ASCO丨肺癌，转移性NSCLC领域口头报告摘要汇总, objectType=article, longId=729299, objectId=fe6ce29299c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe6ce29299c3, replyNumber=0, likeNumber=33, createdTime=2022-12-31, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe6ce29299c3, moduleTitle=2022ASCO丨肺癌，转移性NSCLC领域口头报告摘要汇总, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe6ce29299c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1723671, encodeId=4a391e23671cc, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=Thorac Cancer：伴有罕见突变的晚期或转移性NSCLC患者的真实世界数据, objectType=article, longId=264988, objectId=11502649888a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11502649888a, replyNumber=0, likeNumber=35, createdTime=2022-09-16, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11502649888a, moduleTitle=Thorac Cancer：伴有罕见突变的晚期或转移性NSCLC患者的真实世界数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11502649888a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1723672, encodeId=35461e236728b, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=Transl Lung Cancer Res: 无驱动基因突变的转移性NSCLC患者二线多西他赛+ramucirumab（雷莫芦单抗）治疗的疗效, objectType=article, longId=295315, objectId=4e7b295315f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e7b295315f7, replyNumber=0, likeNumber=41, createdTime=2023-01-20, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e7b295315f7, moduleTitle=Transl Lung Cancer Res: 无驱动基因突变的转移性NSCLC患者二线多西他赛+ramucirumab（雷莫芦单抗）治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e7b295315f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1723670, encodeId=e8a41e236706b, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=J Clin Oncol：Poziotinib治疗既往经治的晚期或转移性NSCLC患者的疗效和安全性, objectType=article, longId=221412, objectId=45d222141221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45d222141221, replyNumber=0, likeNumber=35, createdTime=2022-07-27, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45d222141221, moduleTitle=J Clin Oncol：Poziotinib治疗既往经治的晚期或转移性NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45d222141221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1723669, encodeId=90d11e23669d3, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性, objectType=article, longId=220795, objectId=abf7220e9596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abf7220e9596, replyNumber=0, likeNumber=30, createdTime=2022-03-21, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abf7220e9596, moduleTitle=J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abf7220e9596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1723668, encodeId=a4be1e236685a, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=JNCI：转移性NSCLC患者免疫治疗一定比化疗好吗？并不！, objectType=article, longId=212332, objectId=98b721233212, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98b721233212, replyNumber=0, likeNumber=30, createdTime=2021-12-09, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98b721233212, moduleTitle=JNCI：转移性NSCLC患者免疫治疗一定比化疗好吗？并不！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98b721233212)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1723667, encodeId=a7c51e2366728, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=JCO：派姆单抗一线疗法治疗转移性NSCLC患者的5年预后明显优于化疗！, objectType=article, longId=210240, objectId=c7a6210240c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7a6210240c2, replyNumber=0, likeNumber=39, createdTime=2022-02-17, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7a6210240c2, moduleTitle=JCO：派姆单抗一线疗法治疗转移性NSCLC患者的5年预后明显优于化疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7a6210240c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1723665, encodeId=5ecb1e2366531, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=J Clin Oncol：III期| 派姆单抗联合伊匹单抗治疗PD-L1 TPS≥50%转移性NSCLC（KEYNOTE-598）, objectType=article, longId=206606, objectId=61362066067d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61362066067d, replyNumber=0, likeNumber=38, createdTime=2021-05-01, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61362066067d, moduleTitle=J Clin Oncol：III期| 派姆单抗联合伊匹单抗治疗PD-L1 TPS≥50%转移性NSCLC（KEYNOTE-598）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61362066067d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1723664, encodeId=85871e23664fb, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=CheckMate-870结果公布：欧狄沃240毫克固定剂量30分钟输注在以中国人群为主的经治晚期或转移性NSCLC患者中安全可靠, objectType=article, longId=196839, objectId=69e81968399f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69e81968399f, replyNumber=0, likeNumber=38, createdTime=2021-03-05, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69e81968399f, moduleTitle=CheckMate-870结果公布：欧狄沃240毫克固定剂量30分钟输注在以中国人群为主的经治晚期或转移性NSCLC患者中安全可靠, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69e81968399f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1723666, encodeId=6b7e1e23666a5, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=Clin Cancer Res：根据ctDNA量化的肿瘤突变负荷可很好的预测转移性NSCLC患者是否能从免疫治疗中获益, objectType=article, longId=206791, objectId=9e27206e91ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e27206e91ca, replyNumber=0, likeNumber=26, createdTime=2021-07-04, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e27206e91ca, moduleTitle=Clin Cancer Res：根据ctDNA量化的肿瘤突变负荷可很好的预测转移性NSCLC患者是否能从免疫治疗中获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e27206e91ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1723663, encodeId=5a721e236633e, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=Lancet Oncol：埃罗替尼+雷莫芦单抗治疗EGFR突变型转移性NSCLC, objectType=article, longId=180839, objectId=78aa180839bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78aa180839bf, replyNumber=0, likeNumber=36, createdTime=2020-02-10, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78aa180839bf, moduleTitle=Lancet Oncol：埃罗替尼+雷莫芦单抗治疗EGFR突变型转移性NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78aa180839bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1723661, encodeId=493e1e236612e, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=NEJM：无论PD-L1表达水平帕博利珠单抗一线治疗转移性NSCLC鳞癌生存获益显著, objectType=article, longId=152644, objectId=1a4c15264424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a4c15264424, replyNumber=0, likeNumber=25, createdTime=2019-04-13, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a4c15264424, moduleTitle=NEJM：无论PD-L1表达水平帕博利珠单抗一线治疗转移性NSCLC鳞癌生存获益显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a4c15264424)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1723659, encodeId=3ea71e2365923, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=Keytruda联用化疗药物获得欧盟人用药品委员会批准用于转移性NSCLC的一线治疗, objectType=article, longId=145639, objectId=cbf01456397c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbf01456397c, replyNumber=0, likeNumber=33, createdTime=2018-08-26, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbf01456397c, moduleTitle=Keytruda联用化疗药物获得欧盟人用药品委员会批准用于转移性NSCLC的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbf01456397c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1723662, encodeId=6de81e2366200, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=一线免疫治疗组合未能改善转移性NSCLC的总体存活率, objectType=article, longId=155935, objectId=74d2155935c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74d2155935c0, replyNumber=0, likeNumber=32, createdTime=2019-06-28, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74d2155935c0, moduleTitle=一线免疫治疗组合未能改善转移性NSCLC的总体存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74d2155935c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1723660, encodeId=fcd21e2366030, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=FDA批准辉瑞EGFR抑制剂达克替尼用于EGFR突变的局部晚期或转移性NSCLC患者的一线治疗, objectType=article, longId=149971, objectId=bdf71499e193, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdf71499e193, replyNumber=0, likeNumber=29, createdTime=2019-05-28, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdf71499e193, moduleTitle=FDA批准辉瑞EGFR抑制剂达克替尼用于EGFR突变的局部晚期或转移性NSCLC患者的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdf71499e193)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1723658, encodeId=05cf1e23658fc, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=JNCI：转移性NSCLC：派姆单抗个体化剂量还是固定剂量性价比更高？, objectType=article, longId=118185, objectId=799c1181855c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=799c1181855c, replyNumber=0, likeNumber=30, createdTime=2018-06-08, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=799c1181855c, moduleTitle=JNCI：转移性NSCLC：派姆单抗个体化剂量还是固定剂量性价比更高？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=799c1181855c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1723657, encodeId=f0821e23657d2, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=FDA批准pembrolizumab作为高表达PD-L1转移性NSCLC的一线治疗, objectType=article, longId=81159, objectId=fe928115907, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe928115907, replyNumber=0, likeNumber=30, createdTime=2017-08-30, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe928115907, moduleTitle=FDA批准pembrolizumab作为高表达PD-L1转移性NSCLC的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe928115907)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1723656, encodeId=de161e23656db, content=<a href='/topic/show?id=02ef93401bb' target=_blank style='color:#2F92EE;'>#转移性NSCLC#</a>, objectTitle=招募患者：艾力替尼治疗复发转移性NSCLC患者的有效性和安全性II临床研究, objectType=article, longId=56021, objectId=d1aa5602196, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1aa5602196, replyNumber=0, likeNumber=28, createdTime=2016-02-12, rootId=0, userName=changhe724, userId=230533519197, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1aa5602196, moduleTitle=招募患者：艾力替尼治疗复发转移性NSCLC患者的有效性和安全性II临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1aa5602196)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性NSCLC

2020-05-29

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

2022ASCO丨肺癌，转移性NSCLC领域口头报告摘要汇总

2022-12-31

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

Thorac Cancer：伴有罕见突变的晚期或转移性NSCLC患者的真实世界数据

2022-09-16

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

Transl Lung Cancer Res: 无驱动基因突变的转移性NSCLC患者二线多西他赛+ramucirumab（雷莫芦单抗）治疗的疗效

2023-01-20

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

J Clin Oncol：Poziotinib治疗既往经治的晚期或转移性NSCLC患者的疗效和安全性

2022-07-27

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性

2022-03-21

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

JNCI：转移性NSCLC患者免疫治疗一定比化疗好吗？并不！

2021-12-09

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

JCO：派姆单抗一线疗法治疗转移性NSCLC患者的5年预后明显优于化疗！

2022-02-17

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

J Clin Oncol：III期| 派姆单抗联合伊匹单抗治疗PD-L1 TPS≥50%转移性NSCLC（KEYNOTE-598）

2021-05-01

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

CheckMate-870结果公布：欧狄沃240毫克固定剂量30分钟输注在以中国人群为主的经治晚期或转移性NSCLC患者中安全可靠

2021-03-05

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

Clin Cancer Res：根据ctDNA量化的肿瘤突变负荷可很好的预测转移性NSCLC患者是否能从免疫治疗中获益

2021-07-04

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

Lancet Oncol：埃罗替尼+雷莫芦单抗治疗EGFR突变型转移性NSCLC

2020-02-10

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

NEJM：无论PD-L1表达水平帕博利珠单抗一线治疗转移性NSCLC鳞癌生存获益显著

2019-04-13

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

Keytruda联用化疗药物获得欧盟人用药品委员会批准用于转移性NSCLC的一线治疗

2018-08-26

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

一线免疫治疗组合未能改善转移性NSCLC的总体存活率

2019-06-28

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

FDA批准辉瑞EGFR抑制剂达克替尼用于EGFR突变的局部晚期或转移性NSCLC患者的一线治疗

2019-05-28

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

JNCI：转移性NSCLC：派姆单抗个体化剂量还是固定剂量性价比更高？

2018-06-08

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

FDA批准pembrolizumab作为高表达PD-L1转移性NSCLC的一线治疗

2017-08-30

changhe724 (审核中...)

前往app查看评论内容

#转移性NSCLC#

招募患者：艾力替尼治疗复发转移性NSCLC患者的有效性和安全性II临床研究

2016-02-12

科室
- - 订阅+
  - 更多科室
工具
服务